PCVX Quote, Financials, Valuation and Earnings

Citius Oncology has a net margin of -- compared to Vaxcyte's net margin of --. Vaxcyte's return on equity of -- beat Citius Oncology's return on equity of --.

Vaxcyte has a consensus price target of $132.00, signalling upside risk potential of 370.76%. On the other hand Citius Oncology has an analysts' consensus of $3.00 which suggests that it could grow by 384.57%. Given that Citius Oncology has higher upside potential than Vaxcyte, analysts believe Citius Oncology is more attractive than Vaxcyte.

Vaxcyte has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Citius Oncology has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Vaxcyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Citius Oncology offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vaxcyte pays -- of its earnings as a dividend. Citius Oncology pays out -- of its earnings as a dividend.

Vaxcyte quarterly revenues are --, which are smaller than Citius Oncology quarterly revenues of --. Vaxcyte's net income of -$137.1M is lower than Citius Oncology's net income of -$6.7M. Notably, Vaxcyte's price-to-earnings ratio is -- while Citius Oncology's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vaxcyte is -- versus -- for Citius Oncology. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of -- compared to Vaxcyte's net margin of -117.16%. Vaxcyte's return on equity of -- beat Moderna's return on equity of -29.09%.

Vaxcyte has a consensus price target of $132.00, signalling upside risk potential of 370.76%. On the other hand Moderna has an analysts' consensus of $52.05 which suggests that it could grow by 112.44%. Given that Vaxcyte has higher upside potential than Moderna, analysts believe Vaxcyte is more attractive than Moderna.

Vaxcyte has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Moderna has a beta of 2.231, suggesting its more volatile than the S&P 500 by 123.128%.

Vaxcyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vaxcyte pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

Vaxcyte quarterly revenues are --, which are smaller than Moderna quarterly revenues of $956M. Vaxcyte's net income of -$137.1M is higher than Moderna's net income of -$1.1B. Notably, Vaxcyte's price-to-earnings ratio is -- while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vaxcyte is -- versus 2.97x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Novavax has a net margin of -- compared to Vaxcyte's net margin of -91.76%. Vaxcyte's return on equity of -- beat Novavax's return on equity of --.

Vaxcyte has a consensus price target of $132.00, signalling upside risk potential of 370.76%. On the other hand Novavax has an analysts' consensus of $16.43 which suggests that it could grow by 202.83%. Given that Vaxcyte has higher upside potential than Novavax, analysts believe Vaxcyte is more attractive than Novavax.

Vaxcyte has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Novavax has a beta of 3.148, suggesting its more volatile than the S&P 500 by 214.784%.

Vaxcyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novavax offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vaxcyte pays -- of its earnings as a dividend. Novavax pays out -- of its earnings as a dividend.

Vaxcyte quarterly revenues are --, which are smaller than Novavax quarterly revenues of $88.3M. Vaxcyte's net income of -$137.1M is lower than Novavax's net income of -$81M. Notably, Vaxcyte's price-to-earnings ratio is -- while Novavax's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vaxcyte is -- versus 1.24x for Novavax. Usually stocks with elevated PS ratios are considered overvalued.

Sarepta Therapeutics has a net margin of -- compared to Vaxcyte's net margin of 24.16%. Vaxcyte's return on equity of -- beat Sarepta Therapeutics's return on equity of 20.83%.

Vaxcyte has a consensus price target of $132.00, signalling upside risk potential of 370.76%. On the other hand Sarepta Therapeutics has an analysts' consensus of $157.69 which suggests that it could grow by 214.66%. Given that Vaxcyte has higher upside potential than Sarepta Therapeutics, analysts believe Vaxcyte is more attractive than Sarepta Therapeutics.

Vaxcyte has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Sarepta Therapeutics has a beta of 0.930, suggesting its less volatile than the S&P 500 by 6.993%.

Vaxcyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vaxcyte pays -- of its earnings as a dividend. Sarepta Therapeutics pays out -- of its earnings as a dividend.

Vaxcyte quarterly revenues are --, which are smaller than Sarepta Therapeutics quarterly revenues of $658.4M. Vaxcyte's net income of -$137.1M is lower than Sarepta Therapeutics's net income of $159M. Notably, Vaxcyte's price-to-earnings ratio is -- while Sarepta Therapeutics's PE ratio is 22.07x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vaxcyte is -- versus 2.95x for Sarepta Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.